Shareholder in company (NASDAQ: CRVL) plans 20,000-share stock sale

Rhea-AI Filing Summary

A shareholder has filed a notice of intent to sell 20,000 shares of common stock through J.P. Morgan Securities LLC on or around 02/12/2026 on the NASDAQ market, with an aggregate market value listed as 939,600.

The filing notes that the seller’s shares were originally acquired via transfers from Steven J. Hamerslag in 2006 and 2014, following stock option exercises. It also discloses that a related trust sold 7,000 common shares on 12/11/2025 for gross proceeds of 494,340. The seller represents not knowing any undisclosed material adverse information about the issuer.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue Floor 10 New York NY 10017	20000	939600	51152437	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/04/2014	Transfer	Steven J. Hamerslag, who acquired the shares from the Issuer via a stock option exercise on 2/4/14.			15722	02/04/2014	N/A
Common Stock	12/29/2006	Transfer	Steven J. Hamerslag, who acquired the shares from the Issuer via a stock option exercise on 12/29/06			4278	12/29/2006	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Steven J. Hamerslag and Jean Wells Hamerslag Trust Dated December 9. 1988 2010 MAIN STREET Suite 1020 Irvine CA 92614	Common	12/11/2025	7000	494340

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many CRVL shares are planned for sale under this notice?

The notice covers a planned sale of 20,000 shares of common stock. These shares are expected to be sold through J.P. Morgan Securities LLC on NASDAQ, giving an aggregate market value stated as 939,600 at the time of the filing.

On which exchange will the CRVL shares be sold and when?

The shares are planned to be sold on the NASDAQ stock market. The filing lists an approximate sale date of 02/12/2026, indicating the anticipated timing for when the 20,000 common shares may be sold into the market.

What prior CRVL share sales are disclosed in the last three months?

The filing discloses that the Steven J. Hamerslag and Jean Wells Hamerslag Trust sold 7,000 common shares on 12/11/2025. Those sales generated 494,340 in gross proceeds, providing context on recent selling activity related to the same issuer.

How were the CRVL shares being sold originally acquired?

The shares were acquired via transfers from Steven J. Hamerslag, who obtained them through stock option exercises. One transfer occurred on 02/04/2014 for 15,722 shares and another on 12/29/2006 for 4,278 shares, both recorded as fully paid (N/A consideration).

What representation does the selling CRVL shareholder make about company information?

The seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. This representation is part of the standard attestation included when signing the notice of proposed sale.

How many CRVL shares are stated as outstanding in this notice?

The notice lists 51,152,437 shares of the issuer’s common stock as outstanding. This figure provides a baseline for assessing the scale of the planned 20,000-share sale relative to the issuer’s total common equity base.